The future of the U.S. economy appears to be optimistic. The Federal Reserve has signaled a potential shift towards interest rate cuts in the coming year, providing relief to American households grappling with high inflation. Additionally, the Biden administration’s hope for a “soft landing,” characterized by decreasing inflation without a significant increase in unemployment or
0 Comments
To borrow an old but pertinent Benjamin Graham/Warren Buffett concept, investors should be fearful when others are greedy. That’s a tough principle to apply with Apple (NASDAQ:AAPL) stock because it’s a good, solid company. Yet, even this stock can’t just keep going up without a downward retracement, so caution is advised. This will have important implications
0 Comments
In the vast labyrinth of investment options lies diamonds in the rough—companies often overlooked yet brimming with exceptional potential. Amidst information technology, electronic manufacturing services, semiconductor materials and equipment, and communication services, a triumvirate of stocks stands poised to deliver an astounding 900% return by 2026. These entities exhibit an aura of resilience and strategic
0 Comments
Tax-loss harvesting is a strategic financial tactic investors employ to leverage market downturns for potential gains. The process involves selling securities at a loss to offset or minimize capital gains taxes on profitable investments. Essentially, it allows investors to capitalize on losses by selling underperforming assets. Then, they use those losses to offset taxable gains,
0 Comments
At first glance, electric vehicle (EV) battery technology company QuantumScape (NYSE:QS) might sound like a great business to invest in. After all, QS stock moved higher in November and early December. Yet, caution is definitely advised as QuantumScape’s financial shortcomings can’t be ignored. Besides, as we’ll explain today, a prominent analyst firm published a low price
0 Comments
There’s no doubt about it. It’s been a great year to invest in Nvidia (NASDAQ:NVDA), the most magnificent of the “Magnificent Seven” companies. However, Nvidia isn’t the only artificial intelligence (AI) processor arms race competitor. Indeed, a comeback contender in the AI chip industry should make eager NVDA stock buyers think twice.           
0 Comments
It’s clear to anyone who follows the market which stocks outperformed in 2023. Artificial intelligence and weight loss drug companies led the way. But what about the year ahead? Which securities will ascend to new heights in 2024 and pull the market up with them? Analysts and market commentators are busy with their predictions and
0 Comments
SmileDirectClub (OTCMKTS:SDCCQ) ceased operating on December 8 after it could not restructure through bankruptcy proceedings. The once high-flying provider of dental aligners was one of many at-risk companies entering the final quarter of 2023.  Do you remember all the articles pitting SmileDirect against industry leader Align Technology (NASDAQ:ALGN)? I sure do.  As recently as 2020,
0 Comments
As we usher in a a burgeoning bull market in 2024, it’s paramount to turn our attention to the top cloud computing stocks. The last decade has showcased cloud computing’s role in revolutionizing business operations, enhancing collaboration, scalability, cost-effectiveness, and data security. With these benefits, the cloud computing market is gearing up for massive growth,
0 Comments
Since the end of October, stocks have rallied tremendously, with the S&P 500 soaring 15% and the Russell 2000 jumping 21%. This huge rebound, brought about by greater confidence in the economy and less trepidation about interest rates, resulted in many drastically overvalued stocks. For long-term, risk-tolerant investors, the latter situation created a good opportunity.
0 Comments
Genomics is undeniably medicine’s future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature. Medical advancement lead times, regulatory approval, and expensive R&D combine to make genomics stocks a risky speculative play today while we await
0 Comments